Supernus Pharmaceuticals, Inc.
DE ˙ DB ˙ US8684591089
37,80 € 0,00 (0,00%)
2026-06-04
CENA AKCJI
SecurityDE:S49 / Supernus Pharmaceuticals, Inc.
InstitutionCaptrust Financial Advisors
Latest Disclosed Ownership40,252 shares
Latest Disclosed Value $ 2,080,626
Captrust Financial Advisors reports 116.37% increase in ownership of S49 / Supernus Pharmaceuticals, Inc.

On May 14, 2026 - Captrust Financial Advisors filed a 13F-HR form disclosing ownership of 40,252 shares of Supernus Pharmaceuticals, Inc. (DE:S49) valued at $1,738,886 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 18,603 shares of Supernus Pharmaceuticals, Inc.. This represents a change in shares of 116.37% during the quarter. The current value of the position is $1,521,526 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-14 2026-03-31 13F SUPERNUS PHARMACEUTICALS COM Stock 868459108 40,252 21,649 116.37 2,081 125.11 0.0036
2026-02-17 2025-12-31 13F SUPERNUS PHARMACEUTICALS INC COM Stock 868459108 18,603 188 1.02 925 5.00 0.0018
2025-11-19 2025-09-30 13F SUPERNUS PHARMACEUTICALS INC COM Stock 868459108 18,415 -1,997 -9.78 880 36.86 0.0018
2025-08-15 2025-06-30 13F SUPERNUS PHARMACEUTICALS INC COM Stock 868459108 20,412 2,681 15.12 643 10.86 0.0014
2025-05-15 2025-03-31 13F SUPERNUS PHARMACEUTICALS INC COM Stock 868459108 17,731 337 1.94 581 -7.64 0.0015
2025-02-14 2024-12-31 13F SUPERNUS PHARMACEUTICALS INC COM Stock 868459108 17,394 7,969 84.55 629 114.33 0.0018
2024-11-14 2024-09-30 13F SUPERNUS PHARMACEUTICALS INC COM Stock 868459108 9,425 -819 -7.99 294 6.93 0.0009
2024-08-15 2024-06-30 13F SUPERNUS PHARMACEUTICALS INC COM Stock 868459108 10,244 -87 -0.84 274 -22.16 0.0009
2024-05-15 2024-03-31 13F SUPERNUS PHARMACEUTICALS INC COM Stock 868459108 10,331 1,474 16.64 352 37.50 0.0013
2024-02-14 2023-12-31 13F SUPERNUS PHARMACEUTICALS INC COM Stock 868459108 8,857 -1,502 -14.50 256 -10.18 0.0009
2023-11-15 2023-09-30 13F SUPERNUS PHARMACEUTICALS INC COM Stock 868459108 10,359 10,359 286 0.0011
2023-08-15 2023-06-30 13F SUPERNUS PHARMACEUTICALS INC COM Stock 868459108 0 -6,250 -100.00 0 -100.00
2023-05-15 2023-03-31 13F SUPERNUS PHARMACEUTICALS INC COM Stock 868459108 6,250 209 3.46 226 5.12 0.0010
2023-02-15 2022-12-31 13F SUPERNUS PHARMACEUTICALS INC COM Stock 868459108 6,041 127 2.15 215 7.50 0.0011
2022-11-16 2022-09-30 13F SUPERNUS PHARMACEUTICALS INC COM Stock 868459108 5,914 2,710 84.58 200 115.05 0.0012
2022-08-23 2022-06-30 13F/A-1 SUPERNUS PHARMACEUTICALS INC COM Common Stock 868459108 3,204 221 7.41 93 -3.12 0.0006
2022-08-16 2022-06-30 13F SUPERNUS PHARMACEUTICALS INC COM COM 868459108 3,240 257 94 0.0007
2022-05-16 2022-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 2,983 1,850 163.28 96 190.91 0.0006
2022-02-14 2021-12-31 13F SUPERNUS PHARMACEUTICALS INC COM Common Stock 868459108 1,133 91 8.73 33 17.86 0.0002
2021-11-16 2021-09-30 13F SUPERNUS PHARMACEUTICALS INC COM Common Stock 868459108 1,042 146 16.29 28 0.00 0.0002
2021-08-16 2021-06-30 13F SUPERNUS PHARMACEUTICALS INC COM Common Stock 868459108 896 -20 -2.18 28 16.67 0.0003
2021-05-17 2021-03-31 13F SUPERNUS PHARMACEUTICALS INC COM Common Stock 868459108 916 641 233.09 24 242.86 0.0003
2021-02-16 2020-12-31 13F SUPERNUS PHARMACEUTICALS INC COM Common Stock 868459108 275 50 22.22 7 40.00 0.0001
2020-11-17 2020-09-30 13F SUPERNUS PHARMACEUTICALS INC COM Common Stock 868459108 225 50 28.57 5 25.00 0.0001
2020-08-14 2020-06-30 13F SUPERNUS PHARMACEUTICALS INC COM Common Stock 868459108 175 175 4 0.0001
2020-02-14 2019-12-31 13F SUPERNUS PHARMACEUTICALS INC COM Common Stock 868459108 0 -130 -100.00 0 -100.00
2019-11-14 2019-09-30 13F SUPERNUS PHARMACEUTICALS INC COM Common Stock 868459108 130 0 0.00 4 0.00 0.0001
2019-08-13 2019-06-30 13F SUPERNUS PHARMACEUTICALS INC COM Common Stock 868459108 130 130 4 0.0001
2018-11-15 2018-09-30 13F SUPERNUS PHARMACEUTICALS INC COM Common Stock 868459108 0 -15 -100.00 0 -100.00
2018-08-13 2018-06-30 13F SUPERNUS PHARMACEUTICALS INC COM Common Stock 868459108 15 15 1 0.0001
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.